10 Stocks Jim Cramer Discussed As He Questioned Official Data

3. Merck & Co., Inc. (NYSE:MRK)

Number of Hedge Fund Holders In Q1 2025: 93

Merck & Co., Inc. (NYSE:MRK)’s shares have lost 16% year-to-date as investors continue to be disappointed by the dropping revenue of its GARDASIL HPV drug in China. They are also worried about the patent expiration of the firm’s mega cancer drug KEYTRUDA and wondering whether Merck & Co., Inc. (NYSE:MRK) will be able to follow up with an equally successful successor. However, the shares did gain 3% this week after Pfizer announced that its bladder cancer drug PADCEV improves survival rates when paired with KEYTRUDA. Cramer was impressed as he commented:

“Look at Merck. I mean, Saint Merck. What a tough, what a tough.”

Here are his earlier comments about Merck & Co., Inc. (NYSE:MRK):

“Well, this GARDASIL, when is it? The Chinese are not really helping them sell, because you would have thought the Chinese would. . .and then you’ve got the KEYTRUDA, you know the patent cliff coming up. . .it’s amazing, but they are talking about their animal division. When you’re talking about your animal division you don’t have enough [inaudible] to talk.”